Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AZ's Brilinta Takes Next Step, Gains FDA Approval For Extended Use

This article was originally published in Scrip

Executive Summary

The US FDA has approved AstraZeneca PLC's oral antiplatelet treatment, Brilinta (ticagrelor), in a new indication, allowing the product to be used as a longer term therapy for patients with acute coronary syndrome (ACS).

Advertisement

Related Content

AstraZeneca Groomed Paul Hudson For His New Role … At Novartis

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register